Results 161 to 170 of about 64,832 (295)

First‐Line Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective, Multicenter, Real‐World Study

Head &Neck, Volume 47, Issue 11, Page 2939-2949, November 2025.
ABSTRACT Background In Europe, pembrolizumab with or without chemotherapy is the recommended first‐line treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), with a combined positive score (CPS) ≥ 1. In France, the TPExtreme (TPEx) regimen is preferred for CPS < 1.
Alizée Simon, Cyril Abdeddaim, DucTrung Nguyen, Patrice Gallet, Didier Peiffert, Aurélien Lambert, Lionnel Geoffrois   +6 more
wiley   +1 more source

Chemotherapy-induced nausea and vomiting: exploring patients’ subjective experience

Journal of Multidisciplinary Healthcare, 2016
Noor Salihah,1 Nik Mazlan,2 Pei Lin Lua3 1Faculty of Health Sciences, Universiti Sultan Zainal Abidin, Kampus Gong Badak, Terengganu, 2Kulliyyah of Allied Health Sciences, International Islamic University Malaysia, Pahang, 3Community Health Research
Salihah N, Mazlan N, Lua PL
doaj  

Chemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance)

, 2016
Lisa A. Kottschade, Paul J. Novotny, Alan P. Lyss, Miroslaw Mazurczak, Charles L. Loprinzi, Debra L. Barton   +5 more
openalex   +1 more source

Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting [PDF]

, 2018
Background: We assessed adherence to the European Society of Medical Oncology (ESMO)/Multinational Association of Supportive Care in Cancer recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (CINV) at our institution.
Aebi, Stefan, Burmeister, Henning, Fey, Martin, Gautschi, Oliver, Studer, Cristina   +4 more
core  

Health‐Related Quality of Life in Patients With a Head and Neck Sarcoma: A Mixed‐Methods Study

Head &Neck, Volume 47, Issue 11, Page 3086-3097, November 2025.
ABSTRACT Background Patients with head and neck sarcomas (HNS) face unique health‐related quality of life (HRQoL) challenges due to its disease rarity. This study examined and identified the prevalence of generic‐ and location‐specific HRQoL issues.
E. Koffi, C. S. Padilla, C. Drabbe, W. H. Schreuder, C. Zemouri, D. den Hollander, D. J. Grünhagen, S. Sodergren, S. Singer, R. L. Jones, I. M. E. Desar, L. Fauske, M. Pinto, I. Nixon, S. Salah, Ø. S. Bruland, V. L. M. N. Soomers, M. A. J. van de Sande, J. J. de Haan, C. Verhoef, L. C. Steggink, W. J. van Houdt, T. I. Bootsma, M. T. Tesselaar, W. T. A. van der Graaf, O. Husson   +25 more
wiley   +1 more source

Multicenter phase IV study of palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with non-Hodgkin lymphomas undergoing repeated cycles of moderately emetogenic chemotherapy

, 2013
Brian S. Choi, Gabriela Borsaru, Gianluca Ballinari, Daniel L. Voisin, Nicola Di Renzo   +4 more
openalex   +2 more sources

Randomized Phase II Study of Brentuximab‐Vedotin With High‐Dose Chemotherapy in CD30 Positive Lymphoma

Hematological Oncology, Volume 43, Issue 6, November 2025.
ABSTRACT Patients with Hodgkin lymphoma (HL) or peripheral T‐cell lymphoma (PTCL) who relapse after high‐dose chemotherapy (HDCT) have a dismal prognosis. Brentuximab‐vedotin (BV) is a CD30‐targeting antibody‐drug‐conjugate (ADC) used in first‐line‐, salvage‐, and maintenance‐therapy of HL, as well as first‐line‐ and salvage‐therapy of PTCL. In phase I
Christian Rausch, Ulrike Bacher, Manuela Rabaglio, Corinne Vorburger, Anke Klingenberg, Yara Banz, Michael Daskalakis, Thomas Pabst   +7 more
wiley   +1 more source

Granisetron Transdermal System in the Management of Chemotherapy-Induced Nausea and Vomiting [PDF]

, 2016
H Kitayama
openalex   +1 more source

Real‐world study on fluoropyrimidine‐related toxicity outcomes in cancer patients with select DPYD variant alleles that received DPYD genotype‐guided dosing

International Journal of Cancer, Volume 157, Issue 9, Page 1898-1911, 1 November 2025.
What's new? Fluoropyrimidines, a key component of chemotherapy regimens for a variety of solid tumors, can cause severe toxicity. Patients who have specific genetic variants in the DPYD gene, which encodes an enzyme that inactivates fluoropyrimidines, have increased susceptibility to this toxicity.
Sofía L. J. Peeters, Didier Meulendijks, Zerina Kadric, Sara Ibrovic, Geert‐Jan Creemers, Vanja Milosevic, Matthijs van de Poll, Lieke H. J. Simkens, Birgit A. L. M. Deiman, Hans Gelderblom, Henk‐Jan Guchelaar, Anna M. J. Thijs, Maarten J. Deenen   +12 more
wiley   +1 more source

Comprehensive Framework for Oncology Pharmacist‐Led Parenteral Anticancer Therapy Patient Education: The Opinion of the American College of Clinical Pharmacy Hematology/Oncology Practice and Research Network

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, Volume 8, Issue 11, Page 1202-1214, November 2025.
This narrative review summarizes evidence for effective patient education on parenteral anticancer therapies. The authors propose a structured framework for oncology pharmacist‐led patient education on parenteral anticancer therapies that combines pharmacotherapy knowledge and the application of patient‐centered care.
Erin Hickey Zacholski, Jack Dierckes, David Hartnett‐Quach, Cady Noda, Amanda Sharps, Olivia White, Kyle Zacholski, Shawn P. Griffin   +7 more
wiley   +1 more source